News Archive
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
A study published in Science examines a key player in conditions such as cancer, inflammatory bowel disease, rheumatoid arthritis and asthma and has shown that cells use a sophisticated communication system to coordinate responses to infection and maintain inflammation in the body.
Although teen depression poses a widespread problem for which proven treatments exist, few depressed teens receive any care.
The Impact Of Removing Financial Incentives From Clinical Quality Indicators: Longitudinal Analysis Of Four Kaiser Permanente Indicators - The researchers found the removal of pay-for-performance incentives "was associated with a decrease in performance of about 3% per year on average for screening for diabetic retinopathy and about 1.6% per year for cervical cancer screening" (Lester et al., 5/11). More details about the study and related news coverage are in the May 12 Morning Report.
› Verified 6 days ago